-
This sixteenth edition of Photovoltaics International marks four years of production of the quarterly journal. As always, our focus is on efficiency and quality improvement and cost reduction in manufacturing. As 2012 rolls along, companies are falling by the wayside due to supply and demand issues, ASP declines and drastic governmental subsidy cuts. A clear picture of 2012 is offered through papers from the likes of TÜV Rheinland, Fraunhofer ISE, SEMI PV Group and EPIA, amongst others.
-
This digital interactive Lite sees Tom Cheyney follow Agua Caliente’s progress on becoming one of first truly utility-scale PV power farms, where 40–50MW (AC) will be commissioned by the end of the year. We also feature one of the world’s largest silicon thin-film PV power plants, Avenal; a report on warnings of the collapse of module prices from Solarbuzz and PI-Berlin presents tips on PV module testing. A print version of this edition will be distributed at Solar Power International 2011 in Dallas, Texas.
-
Manufacturing the Solar Future 2012, the second in the Photovoltaics International PV Production Annual series, delivers the next installment of in-depth technical manufacturing information on PV production processes.
Comments
Spectrolab has been shipping product with over 45% eff for years. It doesn’t matter if it’s for concentration or not. Actually concentrated cells have it tougher since their eff falls off with rising temp.
Getting even adequate writers that can do more than regurgitate some pr flack seems harder these days.
This is a 1-sun device, not CPV or HCPV. They are most probably aiming for the AM0 market (space).
@Randy
It is because it is NON-concentrated…
How does this figure?
World’s highest? Spectrolab, Cyrium, Azure, JDSU, Spire, Emcore are multi-junction solar cell manufacturers that are producing cells are 38% and up above 40%.
Unless there is some details missing, it appears Sharp is behind i this industry unless they are driving down costs significantly I see no breakthrough, or there is not enough detail in this article to differentiate Sharp from the other HCPV cell players.